Undiagnosed Sleep Disorder Market Offers Growth Opportunities

리서치사	Koncept Analytics
발행일	2008년 04월	상품코드	64801
페이지 정보	31 pages
가격	US $ 900 ￦ 1,072,300 PDF by E-mail (Single User License) US $ 1,800 ￦ 2,144,700 PDF by E-mail (Corporate Use License)

한글목차
영문목차
관련자료

영문목차

Abstract

There are more than 70 different sleep disorders but the most common ones include insomnia, sleep apnea, restless legs syndrome, and narcolepsy. One of the fastest growing sector in the sleep disorder treatment market is obstructive sleep apnea (OSA) products. OSA affects up to 18 million patients in the US with as many as 85% are undiagnosed. Similarly, 30 million are chronic sufferers of insomnia but only a third of chronic sufferers are receiving treatment. A key reason for this low percentage of people receiving treatment is the side effects associated with most of the insomnia drugs. Over 1.6 million Americans use some form of alternative medicine to treat insomnia.

With rising awareness of sleep disorders, more people are undergoing tests to understand the basics of their sleep disorder condition. Hospitals are opening new sleep centers and upgrading old ones. Patients are looking at innovative aspects in sleep centers which make them feel more homely.

Pharma companies are coming up with new sleeping disorder drugs. Gamma Aminobutyric Acid (GABA) agents dominate the insomnia market. More than a dozen insomnia drugs are in phase II and phase III clinical trials. Major products are Ambien, Ambien CR, Lunesta, Temazepam, and Zolpidem. Respironics and ResMed are the leading competitors in the continuous positive airway pressure (CPAP) market.

The report analyzes the sleep disorder treatment market. The focus is on OSA and insomnia treatment products. The report also profiles the major companies, with a discussion of their key business strategies. It also analyzes the major market and demographic trends prevalent in the sleep disorder treatment market.

1. Sleep Disorders: An Introduction

1.1 Sleep Cycle
1.2 Amount of Sleep Required
1.3 Sleep Disorders
1.4 Insomnia
1.5 Sleep Apnea
1.6 Narcolepsy
1.7 Restless Legs Syndrome
1.8 Treatment & Diagnosis

2. Market Overview

2.1 Worldwide Market
2.2 US Market

3. OSA Market

3.1 Sleep Disordered Breathing Market Breakup
3.2 US Market for OSA Treatment

4. Insomnia Market

5. Market Trends

5.1 Use of Actigraphy for Sleep Disorder Evaluation
5.2 Alternative Medicines for Insomnia
5.3 Opportunities for HME Providers
5.4 Increasing Sleep Centers

6. Demographic Trends

6.1 Sleep Disorders in Older People
6.2 Sleep Disorders in Women
6.3 Sleep Disorders in Children
6.4 Sleep Concerns of Employees

7. Competitive Landscape

7.1 Insomnia Market
- 7.1.1 Drugs in Pipeline for Insomnia
- 7.1.2 Insomnia Market Activity
- 7.1.3 Marketers of Insomnia Drugs
- 7.1.4 Insomnia Market Share
- 7.1.5 Characteristics of Drugs
7.2 OSA Market
- 7.2.1 OSA Sales & Market Share
- 7.2.2 Worldwide Market
- 7.2.3 US Market

8. Company Profiles

8.1 Respironics
- 8.1.1 Overview
- 8.1.2 Business Strategies
- 8.1.3 Product Innovation
- 8.1.4 Strong Distribution Network
- 8.1.5 International Growth
8.2 ResMed
- 8.2.1 Overview
- 8.2.1 Business Strategies
- 8.2.1 Continued Product Development and Innovation
- 8.2.1 Increase Public and Clinical Awareness
- 8.2.1 Expansion into New Clinical Applications
8.3 Neurocrine
- 8.3.1 Overview
- 8.3.2 Business Strategies
- 8.3.3 Building Product Portfolio
- 8.3.4 Identifying Novel Drug Targets
8.4 Neurogen
- 8.4.1 Overview
- 8.4.2 Business Strategies
- 8.4.3 Pursue a Risk-balanced Drug Portfolio
- 8.4.4 Partnering at Optimal Stages
- 8.4.5 Focus on Specialist Care Indications